Table 1 Patient and transplant characteristics

From: Elevated pretransplant serum ferritin is associated with inferior survival following nonmyeloablative allogeneic transplantation

Characteristic

Value

Median age at transplant, years (range)

57 (24–67)

Male gender

40 (62.5%)

Diagnosis

 

 AML

16 (25.0%)

 Non-Hodgkin lymphoma

15 (23.4%)

 Myelodysplastic syndrome

10 (15.6%)

 Myelofibrosis

6 (9.4%)

 Chronic lymphocytic leukemia

6 (9.4%)

 Chronic myelogenous leukemia

5 (7.8%)

 Multiple myeloma

3 (4.7 %)

 Hodgkin lymphoma

2 (3.1%)

 ALL

1 (1.6%)

Median months from diagnosis to transplant (range)

14.1 (2.4–151.6)

Earlier radiation therapy

10 (15.6%)

Earlier courses of chemotherapy

 

 0

8 (12.5%)

 1

14 (21.9%)

 2

16 (25.0%)

 3

10 (15.6%)

 4

8 (12.5%)

 5 or more

8 (12.5%)

Preparative regimen

 

 Fludarabine/TBIa

62 (96.9%)

 CY/thymic irradiationb

2 (3.1%)

Graft source

 

 Peripheral blood

61 (95.3%)

 BM

3 (4.7%)

Donor relationship

 

 Sibling

39 (60.9%)

 Unrelated

25 (39.1%)

  1. Values indicate number of patients (%) unless otherwise indicated.
  2. aTBI dose: 400 cGy in 34 patients and 200 cGy in 28 patients; fludarabine 30 mg/m2 i.v. for 3 days in both regimens.
  3. bCY 50 mg/kg i.v. for 3 days; 700 cGy thymic irradiation single dose; MEDI-507 Ab (anti-CD 2 humanized MoAb as T-cell depleting Ab).
Back to article page